NCT05042375 2022-11-17
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
Jiangsu HengRui Medicine Co., Ltd.
Guangdong Association of Clinical Trials
Jiangsu HengRui Medicine Co., Ltd.